Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 6 Base case analysis: 1-year budget impact analysis of DEX, BORT and LEN/DEX

From: Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective

Treatment regimen

Pharmaceutical costs

Non-pharmaceutical costs

Total costs

Percentage increase from SOC

DEX (SOC)

R 39 877

R 1 333 944

R 1 373 821

 

BORT

R 38 805 287

R 5 655 928

R 44 461 215

3136%

LEN/DEX

R 119 485 065

R 1 189 559

R 120 674 625

8684%